FOLH1 and prostate carcinoma: As shown in Figure 4, the targeted delivery of therapeutic isotopes straight to prostate cancer cells is the method of radiation in cancer lesions using gamma and beta emitters labeled for prostate-specific membrane antigen (PSMA).